Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (311-320 of 345) with videos related to

Pageof 35
Sort By:
Annals of the Rheumatic Diseases|February 10, 2016
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular diseaseKaleb Michaud, Niklas Berglind, Stefan Franzén, et al.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
RMD Open|October 31, 2017
Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programmeHisashi Yamanaka, Johan Askling, Niklas Berglind, et al.
Annals of the Rheumatic Diseases|March 23, 2019
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisLisa Ehlers, Johan Askling, Hans Wj Bijlsma, et al.
Annals of the Rheumatic Diseases|August 21, 2017
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative projectLouise K Mercer, Anne C Regierer, Xavier Mariette, et al.
Arthritis Care & Research|November 30, 2020
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment CoursesBente Glintborg, Ulf Lindström, Daniela Di Giuseppe, et al.
Rheumatology and Therapy|September 26, 2025
Letter to the Editor Regarding "Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases"Claudia A Salinas, Anthony Louder, Jennifer Polinski, et al.
Rheumatology and Therapy|November 13, 2022
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims DatabasesClaudia A Salinas, Anthony Louder, Jennifer Polinski, et al.
Annals of the Rheumatic Diseases|June 22, 2026
Referral pathways and duration of care for musculoskeletal complaints across Europe: an analysis of primary and secondary careGeorgy Gomon, Maxime Raffray, Carlos Betancort Rodríguez, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Pageof 35

Showing results (311-320 of 345) with videos related to

Sort By:
Pageof 35
Annals of the Rheumatic Diseases|February 10, 2016
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular diseaseKaleb Michaud, Niklas Berglind, Stefan Franzén, et al.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
RMD Open|October 31, 2017
Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programmeHisashi Yamanaka, Johan Askling, Niklas Berglind, et al.
Annals of the Rheumatic Diseases|March 23, 2019
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisLisa Ehlers, Johan Askling, Hans Wj Bijlsma, et al.
Annals of the Rheumatic Diseases|August 21, 2017
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative projectLouise K Mercer, Anne C Regierer, Xavier Mariette, et al.
Arthritis Care & Research|November 30, 2020
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment CoursesBente Glintborg, Ulf Lindström, Daniela Di Giuseppe, et al.
Rheumatology and Therapy|September 26, 2025
Letter to the Editor Regarding "Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases"Claudia A Salinas, Anthony Louder, Jennifer Polinski, et al.
Rheumatology and Therapy|November 13, 2022
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims DatabasesClaudia A Salinas, Anthony Louder, Jennifer Polinski, et al.
Annals of the Rheumatic Diseases|June 22, 2026
Referral pathways and duration of care for musculoskeletal complaints across Europe: an analysis of primary and secondary careGeorgy Gomon, Maxime Raffray, Carlos Betancort Rodríguez, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Pageof 35